ANI PHARMACEUTICALS, INC Increase (Decrease) in Accounts Payable and Accrued Liabilities
ANI PHARMACEUTICALS, INC (ANIP) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$1.55 million for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2013-05-10
- ANI PHARMACEUTICALS, INC increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2013-03-31 was -$1.55M.
- ANI PHARMACEUTICALS, INC increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2012-12-31 was -$611.14K.
- ANI PHARMACEUTICALS, INC increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2012-09-30 was -$2.55M.
- ANI PHARMACEUTICALS, INC increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2012-06-30 was -$188.95K.
- ANI PHARMACEUTICALS, INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2012 was -$4.42M, a 3394.64% decline from fiscal 2011.
- ANI PHARMACEUTICALS, INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2011 was $134.10K, a 95.73% decline from fiscal 2010.
- ANI PHARMACEUTICALS, INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2010 was $3.14M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2013-03-31 | -$1.55M 10-Q · filed 2013-05-10 | -$2.16M derived: sum of 2 quarters · filed 2013-05-10 | -$4.72M derived: sum of 3 quarters · filed 2013-05-10 | -$4.91M derived: sum of 4 quarters · filed 2013-05-10 |
| 2012-12-31 | -$611.14K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | -$3.17M derived: sum of 2 quarters · filed 2013-02-28 | -$3.35M derived: sum of 3 quarters · filed 2013-02-28 | -$4.42M 10-K · filed 2013-02-28 |
| 2012-09-30 | -$2.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | -$2.74M derived: sum of 2 quarters · filed 2012-11-08 | -$3.81M 10-Q · filed 2012-11-08 | -$6.67M derived: sum of 4 quarters · filed 2013-05-10 |
| 2012-06-30 | -$188.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | -$1.25M 10-Q · filed 2012-08-01 | -$4.11M derived: sum of 3 quarters · filed 2013-05-10 | -$4.30M derived: sum of 4 quarters · filed 2013-05-10 |
| 2012-03-31 | -$1.06M 10-Q · filed 2013-05-10 | -$3.92M derived: sum of 2 quarters · filed 2013-05-10 | -$4.11M derived: sum of 3 quarters · filed 2013-05-10 | -$5.34M derived: sum of 4 quarters · filed 2013-05-10 |
| 2011-12-31 | -$2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | -$3.05M derived: sum of 2 quarters · filed 2013-02-28 | -$4.28M derived: sum of 3 quarters · filed 2013-02-28 | $134.10K 10-K · filed 2013-02-28 |
| 2011-09-30 | -$190.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | -$1.42M derived: sum of 2 quarters · filed 2012-11-08 | $2.99M 10-Q · filed 2012-11-08 | $2.97M derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-06-30 | -$1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | $3.18M 10-Q · filed 2012-08-01 | $3.16M derived: sum of 3 quarters · filed 2013-02-28 | $3.57M derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-03-31 | $4.41M 10-Q · filed 2012-05-08 | $4.39M derived: sum of 2 quarters · filed 2013-02-28 | $4.79M derived: sum of 3 quarters · filed 2013-02-28 | |
| 2010-12-31 | -$22.93K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $381.94K derived: sum of 2 quarters · filed 2013-02-28 | $3.14M 10-K · filed 2013-02-28 | |
| 2010-09-30 | $404.88K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $3.17M 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | $2.76M 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | -$1.55M 8-K · filed 2013-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |